Observes HyQvia use in adults with multiple myeloma and weakened immunity
Observes how HyQvia is given to adults with myeloma and secondary immunodeficiency.
Plain-language title generated from the registry record
Registry title: Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
Key facts
- Where
- Pilsen and Prague, CzechiaSee the 2 sites
Where in Czechia
- Fakultni nemocnice PlzenPilsen, CzechiaTaking people
- Vseobecna Fakultni NemocnicePrague, CzechiaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Takeda
- Trial code
- NCT05879757
- Record updated
- 18 February 2026
- Original description
In this study, multiple myeloma participants with secondary immunodeficiency (SID) will be treated with HyQvia according to their clinic's standard practice. The study's main aim is to look into infusion parameters of HyQvia administration.Read full original descriptionShow less
A Prospective, Observational Study to Assess the Real-World Usage and Outcomes of HyQvia in Patients With Multiple Myeloma (MM) Diagnosed With Secondary Immunodeficiency (SID)
In this study, multiple myeloma participants with secondary immunodeficiency (SID) will be treated with HyQvia according to their clinic's standard practice. The study's main aim is to look into infusion parameters of HyQvia administration.
Inclusion: Participants who meet all of the following criteria assessed at the time of enrollment are eligible for this study:; Ability and willingness to provide informed consent. For adult participants unable to provide informed consent, informed consent provided by the legally authorized representative (LAR); Has a diagnosis of MM requiring systemic anti-myeloma therapy as per International Myeloma Working Group (IMWG) criteria; Initiated HyQvia treatment as part of routine clinical care no more than 30 days before study enrollment or received no more than 2 doses of HyQvia treatment, whichever occurs first. Participants are also eligible if they newly start HyQvia within 30 days after the enrollment visit; Note: Participants who do not start HyQvia treatment within 30 days of enrollment will be considered as screen failures (and replaced); Age >=18 years old at the time of MM diagnosis; Available medical history records starting from the diagnosis of MM requiring systemic anti-myeloma therapy as IMWG criteria; Life expectancy >6 months at the time of enrollment, per physician assessment; Eastern Cooperative Oncology Group (ECOG) performance status score of <=2; Participants/LAR willing and able to comply with the requirements of the protocol.
Exclusion: Prior use of Ig treatment or prophylaxis within 3 months from the date of enrollment; Has participated in an interventional clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in an interventional clinical study involving a medical product or device during this study; Note: Participants on investigational chimeric antigen receptor-T (CAR-T) cell therapies and/or bispecific antibodies may participate; Planned stem cell transplant during the treatment period or had a prior stem cell transplant: allogeneic transplant at any time, autologous transplant within 3 months of enrollment; Participant has had major surgery within 2 weeks before enrollment, or has not fully recovered from an earlier surgery, or has surgery planned during the time the participant is expected to participate in the study; Note: Participants with planned surgical procedures to be conducted under local anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major surgery; Known hypersensitivity to any of the components of HyQvia; Primary immunodeficiency (PID) or diagnosed with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) and/or active hepatitis C and/or active hepatitis B infection; Serious infection(s) requiring intravenous (IV) treatment at the time of enrollment into the study; except for participants on short-term oral antibiotic therapy; History of malignancy (other than MM) within 3 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, localized prostate cancer or other non-invasive lesion that in the opinion of the investigator, is considered cured with minimal risk of recurrence within 3 years); Participants who meet any of the following criteria assessed at the time of enrollment are not eligible for this study:.